文献速递脑血管病外科神经重症

血浆神经丝轻链作为动脉瘤性蛛网膜下腔出血后不良预后的生物标志物

Plasma Neurofilament Light Chain as a Biomarker for Poor Outcome After Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · World Neurosurg · 2024-06-10

这项前瞻性队列研究在单一三级中心纳入动脉瘤性蛛网膜下腔出血患者,于发病24小时内且血管内或外科干预前采血,发现血浆神经丝轻链预测6个月不良预后的AUC为0.70(0.62-0.78),与WFNS联合未显著提高预测效能,但在按出血严重程度分层时,重型患者神经丝轻链水平显著高于轻型患者。

要点

  • 血浆神经丝轻链预测6个月不良预后AUC为0.70(0.62-0.78),预测效能可接受。
  • 神经丝轻链联合WFNS较单用WFNS未显著提高AUC(0.86,0.80-0.92)。
  • 重型患者神经丝轻链中位数14 pg/mL,显著高于轻型患者7 pg/mL。

核心结论

  • 在整个动脉瘤性蛛网膜下腔出血队列中,血浆神经丝轻链具有可接受的预测效能,但并未改善临床结局预测。
  • 神经丝轻链在基于出血严重程度分层的亚组中可能具有潜在价值。

研究设计与样本

  • 前瞻性队列研究,在单一三级中心开展。
  • 于发病24小时内且血管内或外科干预前采集动脉瘤性蛛网膜下腔出血患者血样。
  • 主要终点为6个月随访时的不良预后。

主要发现

  • 66例(42%)患者出现不良预后。
  • 神经丝轻链预测不良预后的AUC为0.70(0.62-0.78)。
  • 神经丝轻链联合WFNS较单用WFNS模型拟合略高(R² 0.51),AUC未显著提高(0.86,0.80-0.92)。
  • 重型患者神经丝轻链中位数14 pg/mL(IQR 7-32),显著高于轻型患者7 pg/mL(IQR 5-14)。
  • 在重型患者中,死亡者神经丝轻链中位数19 pg/mL(IQR 11-36),显著高于存活者7 pg/mL(IQR 6-13)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurofilament light chain (NfL), a biomarker reflecting neuro-axonal damage, may be useful in improving clinical outcome prediction after aneurysmal subarachnoid hemorrhage (aSAH). We explore the robust and additional value of NfL to neurologic and radiologic grading scales in predicting poor outcome after aSAH. METHODS: In this prospective cohort study conducted in a single tertiary center, blood samples were collected of aSAH patients within 24 hours after ictus and before endovascular/surgical intervention. The primary endpoint was poor outcome at 6 months' follow-up. Receiver operating curves (ROC), area under the curve (AUC, 95% CI) and model-fit (Nagelkerke R2) were calculated for NfL, neurologic grading scale (WFNS), modified Fisher, age ,and sex. A combined ROC and AUC were calculated for variables with an AUC ≥ 0.70. RESULTS: A total of 66 (42%) had poor outcome. The AUC of NfL for poor outcome was 0.70 (0.62-0.78). Combining NfL and WFNS resulted in a slightly higher model fit and not-significantly higher AUC for predicting poor outcome (R2 0.51; AUC 0.86, 0.80-0.92) compared with WFNS alone. When patients were stratified according to hemorrhage severity, median NfL [IQR] levels were significantly higher in poor grade (14 [7-32] pg/mL) than good grade patients (7 [5-14] pg/mL). Within poor grade patients, median NfL [IQR] levels were significantly higher in non-survivors (19 [11-36] pg/mL) than survivors (7 [6-13] pg/mL). CONCLUSION: In the entire aSAH cohort, plasma NfL has an acceptable predictive performance but does not improve clinical outcome prediction. However, NfL may have potential value in subgroups based on hemorrhage severity.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Labib H, Tjerkstra MA, Teunissen CE, et al. Plasma Neurofilament Light Chain as a Biomarker for Poor Outcome After Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2024. PMID: 38866237. doi:10.1016/j.wneu.2024.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。